Goldamit

Goldamit is a prescription oral medication that contains the active ingredient citalopram, a selective serotonin reuptake inhibitor (SSRI) used as an antidepressant. It is marketed in the European Union and is supplied in tablet form, though specific strength information is not disclosed here. As an SSRI, Goldamit works by increasing serotonin levels in the brain to help improve mood and emotional balance and overall well‑being.

Goldamit (citalopram) is primarily prescribed for the treatment of major depressive disorder and may be considered in related mood conditions.

- Management of major depressive disorder in adults. - Adjunctive therapy for persistent depressive symptoms when first‑line treatment is insufficient. - Off‑label use for anxiety disorders under clinical supervision. - May be used in the continuation phase to prevent relapse after acute response. - Treatment of depressive episodes in bipolar disorder under specialist supervision. - May be considered for obsessive‑compulsive disorder when other options are ineffective.

Side effects of Goldamit vary in frequency and severity; they are categorized as common or serious, and patients should be aware of both typical and rare reactions.

Common: - Nausea or upset stomach. - Dry mouth. - Drowsiness or fatigue. - Insomnia or vivid dreams. - Sweating. - Sexual dysfunction such as decreased libido. - Headache. - Dizziness.

Serious: - Serotonin syndrome (agitation, rapid heart rate, high blood pressure). - Severe allergic reaction (rash, swelling, difficulty breathing). - QT interval prolongation leading to cardiac arrhythmia. - Suicidal thoughts, especially in young adults. - Severe hyponatremia (low sodium levels). - Cardiac arrhythmias requiring medical attention.

Before starting Goldamit, healthcare providers assess several safety considerations to minimize risks and ensure appropriate monitoring throughout treatment.

- Evaluate history of bipolar disorder or mania. - Review any previous serotonin syndrome episodes. - Assess liver or kidney impairment that may affect drug clearance. - Consider pregnancy, breastfeeding, and potential fetal risk. - Monitor for worsening depression or emergence of suicidal thoughts. - Use caution in patients taking other QT‑prolonging agents. - Review concomitant use of over‑the‑counter supplements that may affect serotonin levels (e.g., St. John’s wort).

Goldamit can interact with other medicines; some combinations should be avoided while others require careful monitoring to prevent adverse effects.

Avoid: - Monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping an MAOI. - Other serotonergic agents such as tramadol, linezolid, or certain migraine medications. - Drugs known to prolong the QT interval (e.g., certain antiarrhythmics). - Certain antifungal agents (e.g., ketoconazole) that increase citalopram levels.

Use with caution: - Anticoagulants like warfarin (may increase bleeding risk). - Non‑steroidal anti‑inflammatory drugs (NSAIDs) that can affect platelet function. - Alcohol, which may enhance drowsiness. - Anticonvulsants such as carbamazepine that may reduce citalopram efficacy. - Other QT‑prolonging medications under close cardiac monitoring.